Theranostics Market Developments and Growth Opportunities Across 2026–2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Theranostics Market By The End Of 2030?

The theranostics market has experienced substantial expansion recently. This market is projected to expand from $122.98 billion in 2025 to $136.02 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.6%. Historically, this growth has been driven by several key factors, including progress in molecular diagnostics, a rise in the incidence of chronic diseases, the proliferation of oncology-focused research initiatives, the introduction of targeted therapeutics, and the broader development of diagnostic laboratory infrastructure.

The theranostics market is projected to experience swift expansion over the coming years. By 2030, its size is anticipated to reach $205.54 billion, growing at a compound annual growth rate (CAGR) of 10.9%. This projected growth can be attributed to several factors during the forecast period, including increased investments in precision medicine, the growing embrace of AI-powered diagnostic tools, the broadening of theranostic applications within oncology, greater incorporation of genomics into routine clinical practice, and a heightened need for tailored treatment results. Key trends anticipated during this period encompass the enhanced integration of diagnostics with targeted therapies, the rising uptake of personalized medicine platforms, the expanding utilization of molecular imaging techniques, the development of more companion diagnostics, and a sharper focus on treatment pathways specific to individual patients.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10823&type=smp

What Drivers Are Shaping The Future Growth Of The Theranostics Market?

The increasing incidence of cancer is anticipated to drive the expansion of the theranostics market going forward. Cancer, characterized by uncontrolled cell growth affecting multiple organs and leading to considerable global morbidity and mortality, is an area where theranostics, a fusion of therapeutics and diagnostics, presents significant promise for managing both cancer and chronic illnesses. This integrated strategy facilitates personalized and precise treatments through its combined diagnostic and therapeutic functionalities, thereby opening new avenues for innovation within the healthcare sector. Consequently, the growing count of cancer patients will fuel the growth of the theranostics market. For instance, data released in August 2024 by Macmillan Cancer Support, a UK-based organization, indicated that over 3 million individuals in the UK are living with cancer in 2024. This number is projected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. This evidence demonstrates that the increasing prevalence of cancer is a key driver for the theranostics market.

Which Segment Classifications Shape The Theranostics Market?

The theranostics market covered in this report is segmented –

1) By Disease Type: Neurological Disorders, Cardiovascular Diseases, Immunological Disorders, Oncology Diseases, Other Diseases

2) By Technology: Polymerase Chain Reaction, Immunohistochemistry, In-Situ Hybridization, Sequencing, Other Technologies

3) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users

Subsegments:

1) By Neurological Disorders: Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Epilepsy

2) By Cardiovascular Diseases: Coronary Artery Disease, Heart Failure, Atrial Fibrillation, Hypertension

3) By Immunological Disorders: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease, Psoriasis

4) By Oncology Diseases: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer

5) By Other Diseases: Infectious Diseases, Metabolic Disorders, Genetic Disorders

Which Trends Are Influencing The Theranostics Market?

Major companies in the theranostics market are prioritizing the creation of technologically advanced solutions, such as theranostics clinical trials, to boost personalized medicine and enhance patient outcomes by integrating diagnostic and therapeutic approaches into a single treatment strategy. Theranostics clinical trials represent research studies designed to assess the combined application of diagnostic tests and targeted therapies to customize treatment plans for individual patients. These trials aim to ascertain the efficacy of specific treatments based on unique patient biomarkers, thereby furthering personalized medicine. For example, in May 2024, BAMF Health, a US-based cancer treatment center, commenced the COMBAT Trial, formally titled “A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617” (NCT05633160). Notable aspects included its swift activation in just seven weeks via BAMF Health’s BAMF RapAct program, alongside an emphasis on leveraging innovative radiopharmaceuticals targeting the Gastrin-Releasing Peptide receptor (GRPR) to improve therapeutic options for patients with limited treatment avenues.

Which Companies Are Expanding Their Footprint In The Theranostics Market?

Major companies operating in the theranostics market are Abbott Laboratories, Agilent Technologies Inc., Beckman Coulter Inc., Thermo Fisher Scientific Inc, Astellas Pharma, Radiopharm Theranostics Ltd, Alpha-Theranostics, Cardio-Theranostics LLC, Curium, Theradiag, Cell Theranostics, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc, Qiagen NV, Foundation Medicine Inc., Leica Biosystems Nussloch GmBH, Pfizer Inc., Siemens Healthineers, Advanced Accelerator Applications, AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, Bristol-Myers Squibb Company, Danaher Corporation, Illumina Inc., Merck KGaA, Roche Diagnostics Corporation, PerkinElmer Inc.

Read the full theranostics market report here:

https://www.thebusinessresearchcompany.com/report/theranostics-global-market-report

Which Geographic Regions Are Influencing Demand In The Theranostics Market?

North America was the largest region in the global theranostics market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the theranostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Theranostics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10823&type=smp

Browse Through More Reports Similar to the Global Theranostics Market 2026, By The Business Research Company

Radiopharmaceutical Theranostics Global Market Report

https://www.thebusinessresearchcompany.com/report/radiopharmaceutical-theranostics-global-market-report

Music Therapy Global Market Report

https://www.thebusinessresearchcompany.com/report/music-therapy-global-market-report

Antidotes Global Market Report

https://www.thebusinessresearchcompany.com/report/antidotes-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795